📊 CRMD Key Takeaways
Is CorMedix Inc. (CRMD) a Good Investment?
CorMedix demonstrates exceptional financial health with extraordinary growth (617% revenue YoY, 1009% net income YoY) driven by strong demand for its pharmaceutical products. The company maintains fortress-like balance sheet strength with zero debt, abundant liquidity (2.11x current ratio), and industry-leading profitability margins (88.5% gross, 52.3% net). Exceptional cash generation (55.4% FCF margin, $172.8M free cash flow) provides financial flexibility for reinvestment or shareholder returns.
CorMedix shows exceptional fundamental momentum, with revenue up 617% year over year and net income up over 1000%, while sustaining very high gross, operating, and net margins. The balance sheet is healthy, with strong liquidity, no meaningful leverage, and free cash flow conversion that supports continued commercialization and operating flexibility. The main question is whether this unusually strong profitability and growth level is durable rather than a one-period surge.
Why Buy CorMedix Inc. Stock? CRMD Key Strengths
- Explosive revenue and earnings growth (617% and 1009% YoY respectively) indicating strong product market fit and demand
- Exceptional profitability with 52.3% net margin and 40.2% ROE, well above pharmaceutical industry averages
- Pristine balance sheet: zero debt, $144.8M cash, 2.11x current ratio demonstrating superior financial flexibility
- Outstanding cash flow generation with $172.8M free cash flow and 55.4% FCF margin providing capital allocation optionality
- High interest coverage (9160x) and quick ratio (1.94x) confirm no liquidity or solvency concerns
- Significant insider activity (21 Form 4 filings) suggests confidence from company leadership
- Explosive top-line and bottom-line growth, with revenue reaching $311.71M and net income $163.06M
- Outstanding profitability, including 88.5% gross margin, 48.2% operating margin, and 52.3% net margin
- Strong financial health, with $144.84M in cash, a 2.11x current ratio, debt-free leverage, and $172.79M in free cash flow
CRMD Stock Risks: CorMedix Inc. Investment Risks
- Extreme growth rates (617% revenue, 1009% net income) may not be sustainable; requires investigation into growth drivers and market saturation potential
- High concentration of revenue likely tied to specific product(s); product obsolescence or competitive displacement poses significant downside risk
- Pharmaceutical sector regulatory risk including FDA approvals, pricing pressures, and patent cliffs not evident from available metrics
- Rapid growth may mask operational inefficiencies that become apparent during normalization cycles or economic downturns
- Growth may normalize sharply after an exceptionally high year-over-year expansion period
- Pharmaceutical fundamentals can be volatile if revenue is concentrated in a limited product base or launch cycle
- Current profitability may prove difficult to sustain if operating costs, competitive pressure, or commercialization spending rise
Key Metrics to Watch
- Year-over-year revenue growth sustainability (normalize from current 617% to realistic long-term rate)
- Gross margin maintenance as company scales (currently 88.5%, watch for manufacturing/supply chain pressures)
- Operating cash flow trends and cash conversion rates relative to earnings quality
- Product pipeline diversity and development stage to assess long-term growth drivers beyond current products
- Capital allocation decisions regarding debt, share buybacks, or M&A activity
- Revenue growth and net margin durability over the next several filings
- Operating cash flow and free cash flow conversion relative to earnings
CorMedix Inc. (CRMD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 55.4% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 2.11x current ratio provides a solid financial cushion.
CRMD Profit Margin, ROE & Profitability Analysis
CRMD vs Healthcare Sector: How CorMedix Inc. Compares
How CorMedix Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is CorMedix Inc. Stock Overvalued? CRMD Valuation Analysis 2026
Based on fundamental analysis, CorMedix Inc. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
CorMedix Inc. Balance Sheet: CRMD Debt, Cash & Liquidity
CRMD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: CorMedix Inc.'s revenue has grown significantly by 130,196% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.30 indicates the company is currently unprofitable.
CRMD Revenue Growth, EPS Growth & YoY Performance
CRMD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $11.5M | -$2.8M | $-0.05 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CorMedix Inc. Dividends, Buybacks & Capital Allocation
CRMD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for CorMedix Inc. (CIK: 0001410098)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CRMD
What is the AI rating for CRMD?
CorMedix Inc. (CRMD) has a Combined AI Rating of BUY from Claude (STRONG BUY) and ChatGPT (BUY) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CRMD's key strengths?
Claude: Explosive revenue and earnings growth (617% and 1009% YoY respectively) indicating strong product market fit and demand. Exceptional profitability with 52.3% net margin and 40.2% ROE, well above pharmaceutical industry averages. ChatGPT: Explosive top-line and bottom-line growth, with revenue reaching $311.71M and net income $163.06M. Outstanding profitability, including 88.5% gross margin, 48.2% operating margin, and 52.3% net margin.
What are the risks of investing in CRMD?
Claude: Extreme growth rates (617% revenue, 1009% net income) may not be sustainable; requires investigation into growth drivers and market saturation potential. High concentration of revenue likely tied to specific product(s); product obsolescence or competitive displacement poses significant downside risk. ChatGPT: Growth may normalize sharply after an exceptionally high year-over-year expansion period. Pharmaceutical fundamentals can be volatile if revenue is concentrated in a limited product base or launch cycle.
What is CRMD's revenue and growth?
CorMedix Inc. reported revenue of $311.7M.
Does CRMD pay dividends?
CorMedix Inc. does not currently pay dividends.
Where can I find CRMD SEC filings?
Official SEC filings for CorMedix Inc. (CIK: 0001410098) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CRMD's EPS?
CorMedix Inc. has a diluted EPS of $2.04.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CRMD a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, CorMedix Inc. has a BUY rating with 90% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is CRMD stock overvalued or undervalued?
Valuation metrics for CRMD: ROE of 40.2% (sector avg: 15%), net margin of 52.3% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy CRMD stock in 2026?
Our dual AI analysis gives CorMedix Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is CRMD's free cash flow?
CorMedix Inc.'s operating cash flow is $175.0M, with capital expenditures of $2.3M. FCF margin is 55.4%.
How does CRMD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 52.3% (avg: 12%), ROE 40.2% (avg: 15%), current ratio 2.11 (avg: 2).
Why is CRMD's return on equity (ROE) so high?
CorMedix Inc. has a return on equity of 40.2%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 52.3% net margin.